Watch our interview from #ASH25 with Lynette Chee of @PeterMacCC to hear updated results from an ongoing Phase II trial of elritercept in patients with transfusion-dependent LR-MDS.🩸

Click here: 👉

#MDSsm #CTSM #TrialUpdate #HemOnc

Updated results from a Phase II trial of elritercept in LR-MDS

Lynette Chee, MBBS, PhD, The Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, Australia, shares updated ...

ow.ly

Our latest podcast dives into key multiple myeloma updates from #ASH25 🩸
From redefining functional high-risk disease to CAR-T and T-cell engagers.

🎧 Listen here:

Featuring Luciano Costa (@End_myeloma), Nisha Joseph (@nishjo76), Shambavi Richard,

Top updates in myeloma from ASH 2025: the RedirecTT-1 and MajesTEC-3 trials, dual-targeting CAR-T,...

This podcast features key updates in multiple myeloma from ASH 2025. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham,...

ow.ly

Could progression of disease within 36 months (POD36) of starting first-line targeted therapy be used as a clinical tool to identify high-risk patients with CLL?🩸

@hampel_p of @MayoClinic provides insight into this in a video interview from #ASH25:

🎥

POD36 as a prognostic marker and clinical tool in frontline CLL

In this interview, Paul Hampel, MD, Mayo Clinic, Rochester, MN, highlights that progression of disease within 36 mon...

ow.ly

We recently interviewed @michaelwangmd of @MDAndersonNews to hear the results of the Phase I/II trial investigating sonrotoclax monotherapy in patients with R/R #MantleCellLymphoma who had previously been treated with a BTKi.

Click here to watch: 👉

Sonrotoclax monotherapy in R/R MCL previously treated with a BTKi: early Phase I/II results

Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the early results of th...

ow.ly